LAUSR

Key Points Question How does out-of-pocket spending on and the use of lenalidomide therapy differ between commercially insured patients enrolled in high-deductible health plans (HDHPs) and non-HDHPs? Findings In this cohort study of 3163 adults who initiated lenalidomide therapy between 2013 and 2017, HDHP enrollment was associated with a greater likelihood of paying more than $100 per lenalidomide prescription fill compared with non-HDHP enrollment. However, no meaningful differences in patterns of lenalidomide therapy adherence were observed by enrollment status. Meaning Despite higher observed out-of-pocket spending among commercially insured HDHP enrollees, patterns of lenalidomide therapy adherence were similar between HDHP and non-HDHP enrollees.